Key facts
- This page summarizes Michael R. Hayden's Form 4 filing for Xenon Pharmaceuticals Inc. (XENE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 May 2021, 16:13.
Michael R. Hayden - 18 May 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)
- Reporting relationship
- Director
- Issuer ticker
- XENE
- Reported as of
- 18 May 2021
- Net transaction value
- +$13,475
- SEC form
- 4
- Accepted by SEC
- 20 May 2021, 16:13:10 UTC
- Next SEC filing
- 03 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Cassandra Robinson, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael R. Hayden filed Form 4 for Xenon Pharmaceuticals Inc. (XENE) on 20 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$13,475.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XENE
transaction
Common Shares
Options Exercise
- Transaction value
- $13,475
- Shares
- +3,500
- Change %
- +3.1%
- Price
- $3.85
- Shares after
- 116,206
- Date
- 18 May 2021
- Ownership
- Direct
- Footnotes
- F1
XENE
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 92,076
- Date
- 18 May 2021
- Ownership
- By Genworks Inc.
- Footnotes
- F2
XENE
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 114,403
- Date
- 18 May 2021
- Ownership
- By wife
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XENE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -3,500
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 18 May 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 3,500
- Exercise price
- $3.85
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021.
Footnote F2
Michael Hayden is the president and principal beneficial shareholder of Genworks Inc.
Footnote F3
One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date. The original grant date of the option is June 1, 2017.